• publish:2024-04-04 13:21:13

What is Sermaglutide powder used for?

1. What is Sermaglutide powder used for?

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs developed by NovoNordisk, Denmark. Sermaglutide powder is developed based on the basic structure of liraglutide Long-acting dosage form, which is more effective in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA). On the other hand, a once-daily oral formulation of semaglutide is currently in Phase III clinical trials.

Sermaglutide powder is the seventh GLP-1 receptor approved in the world after exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide and benaglutide agonist. At the same time, it is also known as the best hypoglycemic drug in history.

GLP-1, scientific name glucagon-like peptide-1, is a brain-gut peptide secreted by ileal endocrine cells. When GLP-1 binds to the GLP-1 receptor, it can stimulate the secretion of insulin and inhibit the release of glucagon, thereby achieving the effect of lowering blood sugar. In this process, another important chemical, dipeptidylase-4, commonly known as DPP-4, is involved. The main function of DPP-4 is to degrade GLP-1 in the body and keep the content of GLP-1 in balance in the body.

The study found that the lack of GLP-1 secretion is common in patients with type II diabetes, and the already insufficient GLP-1 further weakens the hypoglycemic function under the degradation of DPP-4, resulting in a higher level of blood sugar in patients. Therefore, there are two main ideas for hypoglycemic: one is to develop DPP-4 inhibitors to inactivate DPP-4; the other is to develop biosimilars of GLP-1 to make up for the deficiency of GLP-1.

2. Molecular structural formula:

3. Product preparation:

Semaglutide was prepared by solid-liquid phase synthesis. The linear peptide Aib8, Arg34GLP-1(7-37) and fatty side chain acylating agent were prepared by solid-phase synthesis, and the linear peptide Lys26 was modified with the synthetic fatty chain acylating agent under alkaline conditions to obtain Soma Glutide, and the biological activity of the homemade samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.

4.Indications of semaglutide:

(1) To reduce the risk of cardiovascular events (Major Adverse Cardiovascular Events, MACE), including myocardial infarction, non-fatal heart attack or non-fatal stroke, in adults with type 2 diabetes and other cardiovascular diseases;

(2) For the treatment of obesity

5.The mechanism of action of the product:

As an analog of GLP-1, semaglutide has a similar mechanism of action to GLP-1, and is considered to be one of the treatment options for patients with type 2 diabetes. Its mechanism of action is to promote insulin secretion, inhibit glucagon secretion (lowering blood sugar), and inhibit the emptying of the gastrointestinal tract. Studies have shown that after injection of semaglutide, the number of free meals in subjects is reduced. This is similar to the mechanism of action of native GLP-1 produced in the small intestine in vivo. Different from the native GLP-1 in the body, Sermaglutide powder may directly suppress appetite by directly acting on the feeding center of the hypothalamus to achieve weight loss.

6.Company advantages:

（1）We have ten traditional production lines, 100,000-level purification workshops, and build biogas systems and organic fertilizer production lines to make better use of extracted waste

（2）More than 100 kinds of products such as extracts, proteins and finished products.

（3）The extractor extracts 40 tons of incoming material per day.

（4）Factory industry manufacturer for more than 10 years

（5）ISO, Kosher, Halal, HACCP, ORGANIC certified company.

7.See the science:

（1） “AusPAR: Semaglutide”. Therapeutic Goods Administration (TGA). 2 December 2020. Retrieved 23 February2022.

（2） “Regulatory Decision Summary – Ozempic”. Health Canada. 23 October 2014. Retrieved 2 April 2019.

（3）”FDA approves first oral GLP-1 treatment for type 2 diabetes” (Press release). FDA. 20 September 2019. Retrieved 20 September 2019.

8.Client feedback: